Zoetis (ZTS) Reports Flat Q2 2026 Revenue at $2.5 Billion
Published on · Source: finance.yahoo.com
AI Summary
Summarized by AI from the source belowZoetis Inc. (NYSE: ZTS) reported fiscal Q2 2026 revenue of $2.5 billion, reflecting flat performance and a 1% decline on an organic operational basis. The decline was primarily driven by pressures within the U.S. companion-animal market, which saw a 7% revenue drop and 11% decline in companion-animal product sales. Conversely, livestock revenue grew 12%, bolstered by a 23% increase in the U.S. Livestock segment. The company is looking to restore growth through a pipeline of over 12 potential blockbuster candidates and the recent acquisition of VitalRADS for expanded diagnostics. This matters for investors as it highlights Zoetis's resilience and potential for future growth despite current market challenges.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
About Zoetis Inc. (ZTS)
Zoetis is the world’s largest animal-health company.
The Health Care sector covers pharmaceutical, biotech, device and managed-care companies.
Earlier ZTS news
- Zoetis (ZTS) Director Michael McCallister Buys $233,273 in Shares
- Zoetis (ZTS) Releases DEF 14A Filing for April 30 Meeting
- Zoetis (ZTS) Q3 2024 Revenue Grows 14% Operationally
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
